ProfileGDS5678 / 1426399_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 80% 80% 81% 80% 74% 73% 75% 74% 83% 87% 85% 86% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5263979
GSM967853U87-EV human glioblastoma xenograft - Control 25.6285780
GSM967854U87-EV human glioblastoma xenograft - Control 35.6098180
GSM967855U87-EV human glioblastoma xenograft - Control 45.9680381
GSM967856U87-EV human glioblastoma xenograft - Control 55.7063380
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7202174
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.679773
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9181175
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8145974
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1359283
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6433987
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4509985
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5154686
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1981584